Student or educator? Sign up with your school email and get 6 months of Pro free.
PreprintCited by 180

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Open access
Williamson, Brandi N., Feldmann, Friederike, Schwarz, Benjamin, Meade-White, Kimberly, Porter, Danielle P., Schulz, Jonathan, Doremalen, Neeltje van, Leighton, Ian, Yinda, Claude Kwe, Pérez-Pérez, Lizzette, Okumura, Atsushi, Lovaglio, Jamie, Hanley, Patrick W., Saturday, Greg, Bosio, Catharine M., Anzick, Sarah, Barbian, Kent, Cihlar, Tomas, Martens, Craig, Scott, Dana P., Munster, Vincent J., Wit, Emmie de·2020·bioRxiv (Cold Spring Harbor Laboratory)

Preprint — published as 10.1038/s41586-020-2423-5 · Paper page

Abstract

Background: Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. Methods: To evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory tract disease. Two groups of six rhesus macaques were infected with SARS-CoV-2 and treated with intravenous remdesivir or an equal volume of vehicle solution once daily. Clinical, virological and histological parameters were assessed regularly during the study and at necropsy to determine treatment efficacy. Results: In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs. Virus titers in bronchoalveolar lavages were significantly reduced as early as 12hrs after the first treatment was administered. At necropsy on day 7 after inoculation, lung viral loads of remdesivir-treated animals were significantly lower and there was a clear reduction in damage to the lung tissue. Conclusions: Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS-CoV-2-infected rhesus macaques. These data support early remdesivir treatment initiation in COVID-19 patients to prevent progression to severe pneumonia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.04.15.043166

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 15

  1. 10.1038/srep43395 · DOI · Paper page
  2. Sheahan TP , Sims AC , Graham RL , et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9. · DOI · Paper page
  3. de Wit E , Feldmann F , Cronin J , et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020. · DOI · Paper page
  4. 10.1038/s41467-019-13940-6 · DOI · Paper page
  5. Choy KT , Yin-Lam Wong A , Kaewpreedee P , et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020:104786. · DOI · Paper page
  6. 10.1038/s41422-020-0282-0 · DOI · Paper page
  7. Agostini ML , Andres EL , Sims AC , et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 2018;9. · DOI · Paper page
  8. Munster VJ , Feldmann F , Williamson BN , et al. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. BioRxiv 2020. · DOI
  9. 2010, Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis), Comparative medicine, 60, 389
  10. Corman VM , Landt O , Kaiser M , et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25. · DOI · Paper page
  11. 2015, Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis, mBio, 6, e01491
  12. 10.1038/nmeth.1923 · DOI · Paper page
  13. 10.1101/gr.107524.110 · DOI · Paper page
  14. 10.1038/nature17180 · DOI · Paper page
  15. Sheahan TP , Sims AC , Zhou S , et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020. · DOI · Paper page

Cited by

See all 180

Metadata

Authors
Williamson, B. N., Feldmann, F., Schwarz, B., Meade-White, K., Porter, D. P., Schulz, J., Doremalen, N. V., Leighton, I., Yinda, C. K., Pérez-Pérez, L., Okumura, A., Lovaglio, J., Hanley, P. W., Saturday, G., Bosio, C. M., Anzick, S., Barbian, K., Cihlar, T., Martens, C., Scott, D. P., Munster, V. J., & Wit, E. D.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2020-04-15
OpenAlex
W3016626516
Cited by
180
References
1
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. https://app.cochat.ai/papers/10.1101/2020.04.15.043166
The paper
Williamson, B. N., Feldmann, F., Schwarz, B., Meade-White, K., Porter, D. P., Schulz, J., Doremalen, N. V., Leighton, I., Yinda, C. K., Pérez-Pérez, L., Okumura, A., Lovaglio, J., Hanley, P. W., Saturday, G., Bosio, C. M., Anzick, S., Barbian, K., Cihlar, T., Martens, C., . . . Wit, E. D. (2020). Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2020.04.15.043166

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.